ArticleMMWR. Morbidity and mortality weekly report2023

Evaluation of SARS-CoV-2 RNA Rebound After Nirmatrelvir/Ritonavir Treatment in Randomized, Double-Blind, Placebo-Controlled Trials - United States and International Sites, 2021-2022.

Patrick R Harrington et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.